Article

Circulating Tumor DNA Analysis in Blood for the Prediction of Treatment Response in Patientswith Advanced Non-Small Cell Lung Cancer

2022-01-10

Abstract excerpt

<h4>Introduction: </h4> Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of lung cancer cases. Molecular profiling NGS-based has become a crucial component of clinical management of NSCLC patients. However, despite the main use of tumor tissue, one of the main medical needs is to develop a non-invasive or minimally invasive dynamic tool that can allow the monitoring of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e528252e-0407-54a8-8076-48786569cf25
DOI: 10.32388/n676np

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Analysis in Blood for the Prediction of Treatment Response in Patientswith Advanced Non-Small Cell Lung CancerDOI 10.32388/n676npRead

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read

The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Semantic proximity Read

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsSemantic proximity Read

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.Semantic proximity Read

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Semantic proximity Read

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read

Clinical Utility of ctDNA Analysis in Lung Cancer—A ReviewSemantic proximity Read

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.Semantic proximity Read